Inventor · disambiguated record
Burt Adelman
Also filed as: ADELMAN BURT · ADELMAN BURT A
14 granted patents·8 pending applications·72 citations·filing 2002–2025
91Inventor score
Top patents by PatentIndex Score
22 records- 0195US11084884B2Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedemaTAKEDA PHARMACEUTICALS CO·Filed 2015·Granted Aug 10, 2021·23 cites·17 claims
- 0295US10648990B2Diagnosis and treatment of autoimmune diseasesDYAX CORP·Filed 2018·Granted May 12, 2020·7 cites·10 claims
- 0394US12061206B2Diagnosis and treatment of autoimmune diseasesTAKEDA PHARMACEUTICALS CO·Filed 2020·Granted Aug 13, 2024·3 cites·13 claims
- 0490US11372002B2Assays for determining plasma kallikrein system biomarkersTAKEDA PHARMACEUTICALS CO·Filed 2014·Granted Jun 28, 2022·9 cites·15 claims
- 0588US11286307B2Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attackTAKEDA PHARMACEUTICALS CO·Filed 2016·Granted Mar 29, 2022·7 cites·19 claims
- 0687US11156612B2Methods of determining levels of cleaved and/or intact kininogenTAKEDA PHARMACEUTICALS CO·Filed 2014·Granted Oct 26, 2021·6 cites·15 claims
- 0787US10101344B2Diagnosis and treatment of autoimmune diseasesDYAX CORP·Filed 2014·Granted Oct 16, 2018·8 cites·18 claims
- 0883US12384854B2Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedemaTAKEDA PHARMACEUTICALS CO·Filed 2020·Granted Aug 12, 2025·1 cites·15 claims
- 0980US10913802B2Monoclonal antibody inhibitor of factor XIIADYAX CORP·Filed 2016·Granted Feb 9, 2021·3 cites·15 claims
- 1079US11390687B2Bispecific antibodies against plasma kallikrein and Factor XIITAKEDA PHARMACEUTICALS CO·Filed 2015·Granted Jul 19, 2022·3 cites·26 claims
- 1175US12442824B2Assays for determining plasma kallikrein system biomarkersTAKEDA PHARMACEUTICALS CO·Filed 2021·Granted Oct 14, 2025·0 cites·9 claims
- 1271US7662921B2Methods of treating viral disordersASTELLAS US LLC·Filed 2005·Granted Feb 16, 2010·2 cites·1 claims
- 1366US12240918B2Bispecific antibodies against plasma kallikrein and factor XIITAKEDA PHARMACEUTICALS CO·Filed 2022·Granted Mar 4, 2025·0 cites·16 claims
- 1465US2022169749A1Plasma kallikrein inhibitors and uses thereof for preventing hereditary angioedema attackTAKEDA PHARMACEUTICALS CO·Filed 2021·Application pending·0 cites
- 1564US12415866B2Monoclonal antibody inhibitor of Factor XIIaTAKEDA PHARMACEUTICALS CO·Filed 2020·Granted Sep 16, 2025·0 cites·13 claims
- 1664US2022170936A1Evaluation and treatment of bradykinin-mediated disordersTAKEDA PHARMACEUTICALS CO·Filed 2021·Application pending·0 cites
- 1762US2022315668A1Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attackTAKEDA PHARMACEUTICALS CO·Filed 2022·Application pending·0 cites
- 1852US2018298110A1Plasma kallikrein inhibitors and uses thereof for preventing hereditary angioedema attackDYAX CORP·Filed 2016·Application pending·0 cites
- 1947US2003027744A1Use of a CD40:CD154 binding interruptor to treat immunological complications of the eyeFiled 2002·Application pending·0 cites
- 2044US2013195868A1Treating surface of the eye disordersADELMAN BURT A·Filed 2011·Application pending·0 cites
- 2144US2025263504A1Bispecific antibodies against plasma kallikrein and factor xiiTAKEDA PHARMACEUTICALS CO·Filed 2025·Application pending·0 cites
- 2241US2002119151A1CD154 blockade therapy for therapeutic protein inhibitor syndromeBIOGEN INC·Filed 2002·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Burt Adelman files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →